LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,174
تعداد مقالات10,723
تعداد مشاهده مقاله67,062,546
تعداد دریافت فایل اصل مقاله12,407,468
Najib, Khadijeh Sadat, Barzegar, Hamide, Rezaei, Mehrdad, Davood, Marzieh. (1403). A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial. سامانه مدیریت نشریات علمی, 50(3), 171-178. doi: 10.30476/ijms.2024.102384.3527
Khadijeh Sadat Najib; Hamide Barzegar; Mehrdad Rezaei; Marzieh Davood. "A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial". سامانه مدیریت نشریات علمی, 50, 3, 1403, 171-178. doi: 10.30476/ijms.2024.102384.3527
Najib, Khadijeh Sadat, Barzegar, Hamide, Rezaei, Mehrdad, Davood, Marzieh. (1403). 'A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial', سامانه مدیریت نشریات علمی, 50(3), pp. 171-178. doi: 10.30476/ijms.2024.102384.3527
Najib, Khadijeh Sadat, Barzegar, Hamide, Rezaei, Mehrdad, Davood, Marzieh. A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial. سامانه مدیریت نشریات علمی, 1403; 50(3): 171-178. doi: 10.30476/ijms.2024.102384.3527

A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial

Iranian Journal of Medical Sciences
مقاله 4، دوره 50، شماره 3، خرداد 2025، صفحه 171-178    اصل مقاله (316.95 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2024.102384.3527
نویسندگان
Khadijeh Sadat Najib؛ Hamide Barzegar؛ Mehrdad Rezaei* ؛ Marzieh Davood
Neonatal Research Center, Department of Pediatric, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Surfactant treatment has revolutionized the management of respiratory distress syndrome (RDS) in preterm infants. The present study compared the effectiveness and adverse effects of two natural surfactants, Beracsurf and Curosurf, in premature infants with RDS who required surfactant administration.
Methods: Eighty-four newborns were enrolled in this double-blind randomized controlled trial study, which was conducted in Shiraz, Iran, from 2021 to 2022. The study included all preterm neonates with RDS, who required intubation for stabilization, were on continuous positive airway pressure (CPAP), required oxygen of more than 30% to maintain saturation 90-95%, or had CPAP failure. Using a simple random allocation method, the participants were randomly assigned to receive either Beractant as the case group or Proctant Alpha as the control group. The study assessed outcomes such as hospital length, number of surfactant administration, duration of respiratory support, complications, and mortality in both groups. Data were analyzed using SPSS software and applying independent t tests, Mann-Whitney tests, and Chi square tests. 
Results: Eighty-four neonates were enrolled in the study, with 37 in the control group and 47 in the case group. The duration of hospital stay in the control group was 18.07±13.04 days, while it was 23.59±14.03 days in the intervention group (P=0.07). There were no differences between the two groups in terms of the fraction of inspired oxygen (FIO2) (P=0.46), and complications (P=0.82). However, the intubation period in the Curosurf group was significantly lower (P=0.03). The mortality rate in the Curosurf group was 24.3% (95% CI=10.5%-38.1%); while in the Beracsurf group, it was 10.6% (95% CI=1.8%-19.5%) (P=0.09).
Conclusion: Beracsurf had comparable efficacy to Curosurf and could be considered a viable alternative.
Trial registration number: IRCT20120126008827N3.
کلیدواژه‌ها
Beractant؛ Infant, premature؛ Pulmonary surfactants؛ Respiratory distress syndrome, newborn
مراجع
  1. Lee J, Seong HS, Kim BJ, Jun JK, Romero R, Yoon BH. Evidence to support that spontaneous preterm labor is adaptive in nature: neonatal RDS is more common in “indicated” than in “spontaneous” preterm birth. J Perinat Med. 2009;37:53-8. doi: 10.1515/JPM.2009.036. PubMed PMID: 19099368; PubMed Central PMCID: PMCPMC2887663.
  2. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115:432-50. doi: 10.1159/000499361. PubMed PMID: 30974433; PubMed Central PMCID: PMCPMC6604659.
  3. Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, Shaik NB, Pullattayil SA, Cavallin F, et al. Delivery room CPAP in improving outcomes of preterm neonates in low-and middle-income countries: A systematic review and network meta-analysis. Resuscitation. 2022;170:250-63. doi: 10.1016/j.resuscitation.2021.10.027. PubMed PMID: 34757058.
  4. Van Wyk L, Tooke L, Dippenaar R, Rhoda N, Lloyd L, Holgate S, et al. Optimal Ventilation and Surfactant Therapy in Very-Low-Birth-Weight Infants in Resource-Restricted Regions. Neonatology. 2020;117:217-24. doi: 10.1159/000506987. PubMed PMID: 32454492.
  5. Ng EH, Shah V. Guidelines for surfactant replacement therapy in neonates. Paediatr Child Health. 2021;26:35-49. doi: 10.1093/pch/pxaa116. PubMed PMID: 33552321; PubMed Central PMCID: PMCPMC7850281.
  6. Hentschel R, Bohlin K, van Kaam A, Fuchs H, Danhaive O. Surfactant replacement therapy: from biological basis to current clinical practice. Pediatr Res. 2020;88:176-83. doi: 10.1038/s41390-020-0750-8. PubMed PMID: 31926483; PubMed Central PMCID: PMCPMC7223236.
  7. Aly H, Mohamed MA, Wung JT. Surfactant and continuous positive airway pressure for the prevention of chronic lung disease: History, reality, and new challenges. Semin Fetal Neonatal Med. 2017;22:348-53. doi: 10.1016/j.siny.2017.08.001. PubMed PMID: 28818610.
  8. Ma CC, Ma S. The role of surfactant in respiratory distress syndrome. Open Respir Med J. 2012;6:44-53. doi: 10.2174/1874306401206010044. PubMed PMID: 22859930; PubMed Central PMCID: PMCPMC3409350.
  9. Logan JW, Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Ther Clin Risk Manag. 2009;5:251-60. doi: 10.2147/tcrm.s4029. PubMed PMID: 19436610; PubMed Central PMCID: PMCPMC2697515.
  10. Lane MD, Kishnani S, Udemadu O, Danquah SE, Treadway RM, 3rd, Langman A, et al. Comparative efficacy and safety of late surfactant preparations: a retrospective study. J Perinatol. 2021;41:2639-44. doi: 10.1038/s41372-021-01142-2. PubMed PMID: 34285358; PubMed Central PMCID: PMCPMC8290378.
  11. Mazela J, Merritt TA, Gadzinowski J, Sinha S. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr. 2006;95:1036-48. doi: 10.1080/08035250600615168. PubMed PMID: 16938747.
  12. Gharehbaghi MM, Sarbakhsh P, Mohammadbager H, Gharibzadeh S, Shaseb E. A Randomized, Single-blind, Comparison Trial of Beractant (BeraksurfTM) versus Poractant Alfa (Curosurf®) in the Treatment of Respiratory Distress Syndrome in Preterm Infants. Pharmaceutical Sciences. 2022;29:52-8.
  13. Nourollahi S, Hashemi F, Shafiei E, Pirinegad O. Comparing the effectiveness of curosurf and beraksurf in the treatment of respiratory distress in premature infants. International Journal of Pediatrics. 2022;10:15992-7.
  14. Mussavi M, Mirnia K, Asadollahi K. Comparison of the Efficacy of Three Natural Surfactants (Curosurf, Survanta, and Alveofact) in the Treatment of Respiratory Distress Syndrome Among Neonates: A Randomized Controlled Trial. Iran J Pediatr. 2016;26:e5743. doi: 10.5812/ijp.5743. PubMed PMID: 28203337; PubMed Central PMCID: PMCPMC5297380.
  15. Weiner GM, Zaichkin J. Updates for the Neonatal Resuscitation Program and Resuscitation Guidelines. Neoreviews. 2022;23:e238-e49. doi: 10.1542/neo.23-4-e238. PubMed PMID: 35362042.
  16. Dani C, Corsini I, Bertini G, Fontanelli G, Pratesi S, Rubaltelli FF. The INSURE method in preterm infants of less than 30 weeks’ gestation. J Matern Fetal Neonatal Med. 2010;23:1024-9. doi: 10.3109/14767050903572174. PubMed PMID: 20180736.
  17. Diwakar RK, Khurana O. Cranial Sonography in Preterm Infants with Short Review of Literature. J Pediatr Neurosci. 2018;13:141-9. doi: 10.4103/jpn.JPN_60_17. PubMed PMID: 30090126; PubMed Central PMCID: PMCPMC6057202.
  18. Boshoff Coyles L, Joolay Y, Tooke L. Bovine or Porcine: Does the Type of Surfactant Matter? J Trop Pediatr. 2020;66:534-41. doi: 10.1093/tropej/fmaa011. PubMed PMID: 32112649.
  19. Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163:955-60. doi: 10.1016/j.jpeds.2013.04.053. PubMed PMID: 23769501; PubMed Central PMCID: PMCPMC3779477.
  20. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94:779-84. doi: 10.1111/j.1651-2227.2005.tb01984.x. PubMed PMID: 16188788.
  21. Najafian B, Karimi-Sari H, Khosravi MH, Nikjoo N, Amin S, Shohrati M. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial. Contemp Clin Trials Commun. 2016;3:55-9. doi: 10.1016/j.conctc.2016.04.003. PubMed PMID: 29736457; PubMed Central PMCID: PMCPMC5935855.
  22. Speer CP, Gefeller O, Groneck P, Laufkotter E, Roll C, Hanssler L, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72:F8-13. doi: 10.1136/fn.72.1.f8. PubMed PMID: 7743295; PubMed Central PMCID: PMCPMC2528411.
  23. Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. J Perinatol. 2013;33:119-25. doi: 10.1038/jp.2011.125. PubMed PMID: 21886094; PubMed Central PMCID: PMCPMC3558698.
  24. Mirzarahimi M, Barak M. Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome. Pak J Pharm Sci. 2018;31:469-72. PubMed PMID: 29618436.
  25. Fujii A, Allen R, Doros G, O’Brien S. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome. J Perinatol. 2010;30:671-6. doi: 10.1038/jp.2010.21. PubMed PMID: 20336077.
آمار
تعداد مشاهده مقاله: 167
تعداد دریافت فایل اصل مقاله: 189


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب